Ascentage Pharma Group International: Form 20-F for the period ended Dec 31, 2024
Filed with the SEC on Apr 16, 2025 and accepted by EDGAR at Apr 16, 2025, 16:30 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2024-01-01 to 2024-12-31 | $134.3m | ifrs-full:Revenue |
| Cost of revenue | 12 months2024-01-01 to 2024-12-31 | $4.0m | ifrs-full:CostOfSales |
| Gross profit | 12 months2024-01-01 to 2024-12-31 | $130.4m | ifrs-full:GrossProfit |
| Income tax | 12 months2024-01-01 to 2024-12-31 | $1.4m | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2024-01-01 to 2024-12-31 | −$55.5m | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months2024-01-01 to 2024-12-31 | −$0.18 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2024-01-01 to 2024-12-31 | −$0.18 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2024-01-01 to 2024-12-31 | −$15.3m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2024-01-01 to 2024-12-31 | $3.3m | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2024-12-31 | $122.4m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2024-12-31 | $202.0m | ifrs-full:CurrentAssets |
| Current liabilities | At period end2024-12-31 | $159.8m | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2024-12-31 | $321.1m | ifrs-full:Liabilities |
| Shareholders' equity | At period end2024-12-31 | $36.2m | ifrs-full:EquityAttributableToOwnersOfParent |
Source: SEC EDGAR, the filing index for accession 0001213900-25-032599. Last ingested by Listed: Nov 5, 2026, 12:38 ET. Listed shows no prices and gives no investment advice.